8. Lee SM, Woll PJ, Rudd R et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, Background: We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.
introduction
Epithelial ovarian cancer (EOC) is the fifth most frequent cause of cancer death in women worldwide and second-most lethal gynecologic malignancy [1, 2] . Systemic platinumbased chemotherapy, combined with debulking surgery, is the standard treatment of EOC. However, despite advances in surgery and the development of more effective chemotherapy, relapsed ovarian cancer (ROC) still remains a clinical challenge.
Trabectedin has been proposed to have a multifaceted mechanism of action, arising from its unique ability to bind the minor groove of DNA of tumor cells. Once bound, trabectedin is believed to interact with DNA-binding molecules including transcription factors and DNA repair proteins [3] . Additionally, trabectedin acts on the tumor microenvironment by directly affecting monocytes and tumor-associated macrophages and indirectly by inhibiting the secretion of inflammatory mediators involved in different pathophysiological processes, such as inflammatory cell recruitment or tumor angiogenesis [4, 5] . Trabectedin, in combination with pegylated liposomal doxorubicin (PLD), is approved in >65 countries across the world for treating patients with relapsed platinum-sensitive OC [3] . Both trabectedin and PLD can induce double-stranded breaks in DNA, which triggers a series of events that interfere with the cell cycle and ultimately lead to tumor cell death [3] . An efficient transcription-coupled nucleotide excision repair (TC-NER) system is necessary for the repair of these double-strand breaks. XPG is a component of the TC-NER complex responsible for the 3 0 incision and for 'trapping' the trabectedin/DNA complex, through establishment of hydrogen bonds with the C-3 ring of trabectedin and forming a T-DNA adduct, which in turn allows multiple-strand breaks that are difficult to repair. Mutated forms of XPG are hypothesized to be inefficient in this function and result in decreased sensitivity to trabectedin treatment in patients than wild type, presumably through less DNA breakage. While BRCA1 protein surveys for DNA damage and leads to repair of DNA breaks by attracting the TC-NER complex, BRCA2 mediates the core mechanism of homologous recombination (HR) by loading other proteins to the double-strand break sites and stalled DNA replication forks. Mutations in BRCA1 and BRCA2 presumably are associated with a better response to drug treatment because of the inefficiency in DNA end resection during HR.
A randomized phase 3 study (ET743-OVA-301) has demonstrated the efficacy and safety of trabectedin + PLD versus PLD alone in 672 patients with ROC [6, 7] . An exploratory analysis of this study was carried out with an objective to determine whether mutation in the regulators of HR DNA repair pathway (BRCA1) and TC-NER DNA repair pathway (XPG) could impact the clinical benefit achieved from trabectedin + PLD combination in patients with ROC. Figure S1 , available at Annals of Oncology online). The details of inclusion and exclusion criteria as well as efficacy and safety results are published elsewhere [6, 7] . Briefly, eligible patients were ≥18 years of age with sporadic advanced ROC and failed first-line platinum-based chemotherapy. Efficacy, in terms of response rate (RR) and progression-free survival (PFS), was assessed in accordance with Response Evaluation Criteria in Solid Tumors [8] by investigators. Demographic and baseline characteristics, such as age, race, baseline ECOG score, histology grade, platinum sensitivity status, baseline liver/lung involvement and number of cycles, were recorded.
The study protocol was approved by the institutional review board or independent ethics committee at each site. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with Good Clinical Practices, and applicable regulatory requirements. All patients provided written informed consent. Only patients who signed a separate informed consent form indicating their willingness to participate in the optional pharmacogenomic and biomarker analyses were included in this exploratory analysis.
DNA extraction
Following patient consent, the DNA extracted from EDTA-preserved whole blood was evaluated by genotyping for a defined set of genes (for details of assay methods, supplementary information 1 and Table S1 , available at Annals of Oncology online).
Fifty-nine BRCA1 variants categorized as clinically important based on the Breast Cancer Information Core (BIC) database for BRCA mutation analyses were analyzed using two probe pools (supplementary Table S2 , available at Annals of Oncology online) and the SNPlex™ Genotyping System method (Applied Biosystems) following the manufacturer's instructions. All patients were genotyped for the D1104H (exon 15, G>C; rs17655) mutation of the XPG gene and for the following alleles in the BRCA1 gene: 1135insA, 1499insA, 1675delA, 185delAG, 2312del5, 2594delC, 2804delAA, 3166ins5, 3600del11, 3819del5, 3875del4, 4154delA, 5382insC, 816delGT, A1708E, C61G, D1692N, E1060X, E1107X, E1221X, E1250X, E1373X, E1683X, E1725X, E445X, E720X, E732X, E755X, E908X, IVS21-36del510, K583X, K614X, K679X, L1080X, Q1096X, Q1111X, Q1135X, Q1281X, Q1395X, Q1447X, Q526X, Q541X, Q544X, Q563X, Q780X, Q957X, R1203X, R131X, R1443X, R1495M, R1699W, R1751X, R1835X, R71G, S713X, W1815X, W1837X, W321X and Y1113X.
statistical analysis
Since this analysis was exploratory, no multiple comparisons were adjusted. The primary single-marker association analysis was aimed at identifying genotypes associated with clinical study end points (PFS, RR and OS). log-rank test was carried out for PFS and OS between trabectedin + PLD and PLD alone groups; a P-value of ≤0.05 was considered significant.
results patient characteristics
Of the 672 patients participating in the study, 337 were randomized to trabectedin + PLD and 335 to PLD alone. Of these, 264 patients (trabectedin + PLD: n = 135; PLD: n = 129) gave consent for pharmacogenomics analysis. The demographics and baseline characteristics were similar across both treatment groups (Table 1) .
genomic analysis of BRCA1 and its correlation with clinical outcomes
A total of 41 of 264 patients (16%) had a germline mutation in BRCA1 (BRCA1 mut ; Table 2 ). Of these, 17 patients were treated with the trabectedin + PLD, and 24 were treated with PLD alone.
Overall, 82 (31%) of the 264 patients were responders (patients with CR + PR); a higher proportion of patients in either of the treatment groups with BRCA1 mut (20/41; 49%) responded versus BRCA1
wt patients (62/223; 28%). Among the patients with BRCA1 mut , the trabectedin + PLD-treated patients had a better RR (Table 2 ). This increased sensitivity correlated with improved outcomes (PFS and OS). Patients with BRCA1 mut who were treated with trabectedin + PLD had significantly longer PFS than PLD alone-treated (median PFS: 13.5 versus 5.5 months, P = 0.0002; Figure 1 ). Also, patients with BRCA1 mut who were treated with trabectedin + PLD had significantly longer OS versus those with BRCA1 mut who were treated with PLD alone (median OS: 23.8 versus 12.5 months, P = 0.0086) (Figure 1 ). On the other hand, the PFS and OS in BRCA1 wt patients treated with trabectedin + PLD was not significantly different compared with BRCA1 wt patients who were treated with PLD alone (median PFS: 6.0 versus 5.4 months, P = 0.2185; median OS: 19.1 versus 19.3 months, P = 0.9377).
Of the BRCA1 mut patients, 31 patients were platinum-sensitive and 10 were platinum-resistant. Platinum sensitivity was balanced across both treatment groups (trabectedin + PLD: n = 18, 75%; PLD alone: n = 13, 76%). Platinum-sensitive patients with BRCA1 mut who were treated with trabectedin + PLD had significantly longer PFS (median PFS: 13.6 versus 5.5 months, P = 0.0001) and longer OS (median OS: 27.4 versus 18.7 months, P = 0.0093) versus those with BRCA1 mut who were treated with PLD alone (Figure 2 ). On the other hand, the platinum-resistant patients with BRCA1 mut who were treated with trabectedin + PLD had similar PFS (median PFS: trabectedin + PLD: 4.8 versus 4.6 months, P = 0.5988) and OS (median OS: 13.4 versus 12.1 months, P = 0.4451) versus those with BRCA1 mut who were treated with PLD alone.
genomic analysis of XPG and its correlation with clinical outcomes
A total of 264 blood samples were analyzed for the D1104H mutation. The overall frequency of homozygous (C/C) D1104H Table 1 . Patient demographics and baseline characteristics of patients studied for BRCA1 and XPG status in exploratory analysis ). There were no significant (P < 0.05) differences found between any of the XPG genotypes (C/C versus G/−) and RR in the total germline population or by the treatment group (Table 2) .
Patients with XPG mut had a trend toward shorter OS compared with XPG wt (median OS: 18.7 versus 19.6 months; P = 0.1770). There were no differences in OS and PFS of patients with XPG mut between the two treatment arms, though the trabectedin + PLD-treated patients with XPG mut tended to have shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) versus those without mutation (Table 3) . Similar results were observed in PLD alone-treated patients with and without XPG mutations; however, the OS and PFS were worse than the trabectedin + PLD-treated patients with and without mutations (Table 3) . Based on the platinum sensitivity, platinum-resistant patients with XPG mut who were treated with trabectedin + PLD had significantly (P = 0.0027) shorter median PFS (1.3 months) versus (17) 187 (247) 8 (9) 98 (120) those with XPG wt undergoing the same treatment (3.7 months). These results were corroborated by a similar trend demonstrated by OS (P = 0.0777, 5.9 versus 12.0 months) in these groups. There were no significant PFS findings for patients with or without an XPG mutation who were treated with PLD alone. There was no significant difference in the OS of platinumresistant patients with or without mutations and by the treatment arm. There was no significant difference seen in PFS and OS (18.7 versus 25.3 months; P = 0.1811) between the two treatments in platinum-sensitive patients with and without mutations.
discussion
Previous in vitro studies demonstrated that trabectedin sensitivity depends on the status of both the TC-NER DNA repair pathway and the HR DNA repair pathway. However, the exact mechanism of action for trabectedin has not been fully elucidated in clinical settings. This exploratory analysis of the data from the OVA-301 study, a phase 3 study, investigated the impact of predictive biomarkers involved in the TC-NER DNA repair pathway (XPG) and the HR DNA repair pathway (BRCA1) on trabectedin sensitivity. The findings indicated that patients with BRCA1 mutant alleles demonstrated improved outcomes among trabectedin + PLD-treated patients, whereas XPG may be a biomarker of poor outcome in those treated with trabectedin + PLD. Patients with BRCA1 mut who were treated with trabectedin + PLD had a significantly better RR (63%) versus those without a mutation who were treated with trabectedin + PLD (35%). There was also a significantly longer PFS and OS in patients with BRCA1 mut versus those without mutations.
The findings of the phase 3 study demonstrated an increased RR [6] and improved PFS, and a trend toward improved OS following trabectedin + PLD treatment versus PLD alone-treated patients (median PFS: 7.3 versus 5.8 months, P = 0.0190; median OS: 20.5 versus 19.4 months, P = 0.1506). Furthermore, the median PFS observed in the trabectedin + PLD-treated platinum-sensitive patients with BRCA1 mut was significantly longer compared with those without mutations (13.6 versus 5.5 months). The overall median PFS observed in the original study in trabectedin + PLD-treated platinum-sensitive patients was 9.2 months and an RR was 35.3% [6] . This suggests that the sensitivity of the tumor to the cytotoxic effects of the drug combination may have determined the clinical benefit. Consistent with these observations, a recently reported prospective phase 2 study demonstrated the value of trabectedin as a treatment option in patients with platinum-sensitive advanced OC with BRCA mutation (41% ORR) following failed treatment with multiple platinum regimens [9] .
Over the past two decades, significant progress has been made in elucidating the functions of BRCA1 and BRCA2 and their mutations on cancer risk and prognosis. Sensitivity of cells deficient in homologous repair has been confirmed in the clinic, as the tumor expression of BRCA1 or BRCA2 is shown to be inversely related to the response in patients with sarcomas treated with trabectedin [10] . With growing awareness of the prognostic importance of BRCA1 mutations in changing the approach to OC treatment, it is increasingly likely that awareness of the patients' BRCA mutation status may be important in treatment recommendations and designing further clinical studies. Several earlier studies have shown that patients who have BRCA1 germline mutations and who develop EOC may have improved survival when compared with those with sporadic EOC [10] [11] [12] . An earlier study conducted using paclitaxel, a mitotic inhibitor, demonstrated a clinically significant benefit in PFS (14 months) and OS (36 months) in patients with tumors having aberrant BRCA1 expression who were treated with cisplatin and paclitaxel chemotherapy compared with those whose tumors had normal expression of BRCA1 [13] . The study had suggested that decreased BRCA1 expression predicts for an improved response to platinum-sensitive agents. Another study using olaparib, a poly ADP-ribose polymerase inhibitor, showed that the median PFS was 8.4 months in olaparib-treated patients with BRCA1 mut versus 4.8 months in placebo-treated patients with BRCA1 mut [14] . In this analysis, patients with BRCA1 mut who were treated with trabectedin + PLD had significantly longer PFS and OS than PLD alone-treated patients. Owing to the limited number of patients with a germline mutation in BRCA2 (n = 4, 1.5%), we could not investigate whether mutations in BRCA2 could also impact the clinical benefit achieved from trabectedin + PLD combination in patients with ROC. However, findings of an earlier study revealed that the impact of BRCA1 and BRCA2 mutations on survival appeared to be similar among patients with both localized and advanced stage tumors, and among both serous and non-serous tumors [15] .
The overall population frequency of BRCA mutations observed in our study (10%) is similar to reports in historical literature [16] . The incidence rate of BRCA1 mutations seen in relapsed/ refractory patients in this study was 16%. It should, however, be noted that only known BRCA1 and 2 variants with clinical significance in the BIC database were selected for analysis and thus, this analysis may have missed few other functionally significant variants that are less characterized and/or are rare.
Patients with XPG mutation and who were treated with trabectedin + PLD exhibited a trend toward shorter PFS versus those without XPG mutation. It is known that unlike platinum compounds, trabectedin is more cytotoxic in cells with an efficient TC-NER system [17] and XPG is an important component of this repair system. Hence, our results are consistent with the expected biological ramifications of XPG mutations, which suggest that XPG is involved in TC-NER repair complex, and mutations in XPG may affect trabectedin efficacy. However, there were no significant differences between any of the XPG genotypes (C/C compared with G/−) and RR in the total population or by the treatment arm. This may be due to the limited number of patients with XPG mutations. It is also unclear whether this effect is due to the platinum-resistant population, which may have driven the overall trend as seen in the total population.
A limitation of this hypothesis-generating analysis is a small sample size and is exploratory nature. This analysis was carried out on a subset of patients randomized in the OVA-301 study who had provided consent for pharmacogenomics evaluations. Among those patients who consented for the evaluation, an even smaller percentage of the patients had either BRCA1 or XPG mutations.
In conclusion, these results suggest that patients with BRCA1 mutation may receive increased benefit from the combination of trabectedin + PLD treatment versus PLD alone in ROC, while the presence of a XPG mutation may be a poor indicator of prognosis in ROC. Prospective evaluation of XPG and BRCA1 as prognostic markers is critical, as they may predict overall survival and outcomes to chemotherapy, particularly in patients with OC, as there are currently no good clinical measures to predict response to standard platinum-based chemotherapy. Furthermore, since patients are now assessed for BRCA status in several countries, prospective evaluation of BRCA status before treatment may be important in evaluating DNA-damaging agents and thus, may significantly impact the interpretation of clinical studies. Future studies initiated for treating OC (Clinicaltrials.gov NCT 01846611) are now designed to prospectively include the BRCA1 stratification during screening the patient population.
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